AUTHOR=Yang ZiYan , Wang Wei , Wang Xiaojia , Qin ZhiQuan 

TITLE=Cardiotoxicity of Epidermal Growth Factor Receptor 2-Targeted Drugs for Breast Cancer

JOURNAL=Frontiers in Pharmacology

VOLUME=Volume 12 - 2021

YEAR=2021

URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.741451

DOI=10.3389/fphar.2021.741451

ISSN=1663-9812

ABSTRACT=Breast cancer is the most common tumor in women, and its number is increasing year over year. Human epidermal growth factor receptor 2 (HER2 or ErbB2) overexpression is responsible for 20% to 25% of invasive breast cancers and is associated with poor prognosis. HER2 therapy has significantly improved overall survival in patients with HER2(+) breast cancer. However, despite its therapeutic benefits, its cardiotoxicity is a major concern, especially when used in conjunction with anthracyclines. The main anti-ErbB2-targeting drugs with cardiotoxicity are the mechanism of cardiotoxicity induced by drugs is not fully understood. Currently, NGR1 / HER-2 inhibiting HER dimer formation causes increasing ROS in mitochondria, and inhibition of PI3K/Akt and Ras/MAPK pathways directly leads to cell apoptosis. MMP2 are newly discovered pathways. In addition, although ACEIs /ARBs/β-blockers and other drugs have an inhibitory effect on heart dysfunction caused by ErbB2-targeted drugs. NT-proBNP does well in  monitored TIC during target drugs treatment and a predictive effect on disease prognosis. It is non-invasive, inexpensive, reproducible, and worthy of the attention of clinicians. NT-proBNP may serve as a biological marker for clinical prediction of the occurrence of cardiotoxicity.